Cargando…

Objective physical and mental markers of self‐reported fatigue in women undergoing (neo)adjuvant chemotherapy for early‐stage breast cancer

BACKGROUND: Objective, treatment‐independent markers of cancer‐related fatigue are needed to advance clinical trials. In the current study, the authors evaluated physical, neurocognitive, and serologic markers for correlation with self‐reported fatigue before and after (neo)adjuvant chemotherapy for...

Descripción completa

Detalles Bibliográficos
Autores principales: Mortimer, Joanne E., Waliany, Sarah, Dieli‐Conwright, Christina M., Patel, Sunita K., Hurria, Arti, Chao, Joseph, Tiep, Brian, Behrendt, Carolyn E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427709/
https://www.ncbi.nlm.nih.gov/pubmed/28061004
http://dx.doi.org/10.1002/cncr.30426
_version_ 1783235682476490752
author Mortimer, Joanne E.
Waliany, Sarah
Dieli‐Conwright, Christina M.
Patel, Sunita K.
Hurria, Arti
Chao, Joseph
Tiep, Brian
Behrendt, Carolyn E.
author_facet Mortimer, Joanne E.
Waliany, Sarah
Dieli‐Conwright, Christina M.
Patel, Sunita K.
Hurria, Arti
Chao, Joseph
Tiep, Brian
Behrendt, Carolyn E.
author_sort Mortimer, Joanne E.
collection PubMed
description BACKGROUND: Objective, treatment‐independent markers of cancer‐related fatigue are needed to advance clinical trials. In the current study, the authors evaluated physical, neurocognitive, and serologic markers for correlation with self‐reported fatigue before and after (neo)adjuvant chemotherapy for patients with early‐stage breast cancer. METHODS: Women with AJCC TNM Stage I‐III breast cancer consented to assessment before and after the completion of 4 cycles of dose‐dense doxorubicin and cyclophosphamide. Assessment included self‐reported fatigue (using the Brief Fatigue Inventory), depression (using the Center for Epidemiologic Studies–Depression Scale [CES‐D]), Pittsburgh Sleep Quality Index, and 28 objective measures (grip strength in dominant and nondominant hands, 6‐minute walk, daily total energy expenditure, 14 neurocognitive tests, and 10 serologic markers). Generalized linear regression models of fatigue were constructed (1 model per marker), and adjusted for depression, timing before/after chemotherapy, menopausal status, obesity, and educational level. P values were adjusted to control the False Discovery Rate. RESULTS: Of 28 subjects, 3 withdrew without completing baseline assessments. Prechemotherapy and postchemotherapy data were available for the evaluation of physical measures (25 subjects aged 50.6 ± 9.5 years), neurocognitive tests (22 subjects), and serologic markers (10 subjects). On covariate‐adjusted analysis, interleukin (IL)‐12 was found to be associated with fatigue at both assessments (P<.01). Serum eotaxin (P < .01), IL‐1RA (P < .01), monocyte chemoattractant protein 1 (MCP‐1) (P<.01), and performance on 2 neurocognitive (Trail Making) tests (P<.01 and P = .02, respectively) were found to be inversely associated with fatigue before chemotherapy but not afterward, whereas daily energy expenditure, serum MCP‐1, and serum macrophage inflammatory protein 1a (MIP‐1a) were found to be associated with fatigue after receipt of chemotherapy but not before (P<.01 for each). The association between energy expenditure and fatigue was detectable only if an actively athletic subject with outlier values of energy expenditure was excluded. CONCLUSIONS: Serum IL‐12 merits confirmatory testing as an objective, treatment‐independent measure of fatigue in patients with early‐stage breast cancer. Cancer 2017;123:1810–1816. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
format Online
Article
Text
id pubmed-5427709
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54277092017-06-20 Objective physical and mental markers of self‐reported fatigue in women undergoing (neo)adjuvant chemotherapy for early‐stage breast cancer Mortimer, Joanne E. Waliany, Sarah Dieli‐Conwright, Christina M. Patel, Sunita K. Hurria, Arti Chao, Joseph Tiep, Brian Behrendt, Carolyn E. Cancer Original Articles BACKGROUND: Objective, treatment‐independent markers of cancer‐related fatigue are needed to advance clinical trials. In the current study, the authors evaluated physical, neurocognitive, and serologic markers for correlation with self‐reported fatigue before and after (neo)adjuvant chemotherapy for patients with early‐stage breast cancer. METHODS: Women with AJCC TNM Stage I‐III breast cancer consented to assessment before and after the completion of 4 cycles of dose‐dense doxorubicin and cyclophosphamide. Assessment included self‐reported fatigue (using the Brief Fatigue Inventory), depression (using the Center for Epidemiologic Studies–Depression Scale [CES‐D]), Pittsburgh Sleep Quality Index, and 28 objective measures (grip strength in dominant and nondominant hands, 6‐minute walk, daily total energy expenditure, 14 neurocognitive tests, and 10 serologic markers). Generalized linear regression models of fatigue were constructed (1 model per marker), and adjusted for depression, timing before/after chemotherapy, menopausal status, obesity, and educational level. P values were adjusted to control the False Discovery Rate. RESULTS: Of 28 subjects, 3 withdrew without completing baseline assessments. Prechemotherapy and postchemotherapy data were available for the evaluation of physical measures (25 subjects aged 50.6 ± 9.5 years), neurocognitive tests (22 subjects), and serologic markers (10 subjects). On covariate‐adjusted analysis, interleukin (IL)‐12 was found to be associated with fatigue at both assessments (P<.01). Serum eotaxin (P < .01), IL‐1RA (P < .01), monocyte chemoattractant protein 1 (MCP‐1) (P<.01), and performance on 2 neurocognitive (Trail Making) tests (P<.01 and P = .02, respectively) were found to be inversely associated with fatigue before chemotherapy but not afterward, whereas daily energy expenditure, serum MCP‐1, and serum macrophage inflammatory protein 1a (MIP‐1a) were found to be associated with fatigue after receipt of chemotherapy but not before (P<.01 for each). The association between energy expenditure and fatigue was detectable only if an actively athletic subject with outlier values of energy expenditure was excluded. CONCLUSIONS: Serum IL‐12 merits confirmatory testing as an objective, treatment‐independent measure of fatigue in patients with early‐stage breast cancer. Cancer 2017;123:1810–1816. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. John Wiley and Sons Inc. 2017-01-06 2017-05-15 /pmc/articles/PMC5427709/ /pubmed/28061004 http://dx.doi.org/10.1002/cncr.30426 Text en © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Mortimer, Joanne E.
Waliany, Sarah
Dieli‐Conwright, Christina M.
Patel, Sunita K.
Hurria, Arti
Chao, Joseph
Tiep, Brian
Behrendt, Carolyn E.
Objective physical and mental markers of self‐reported fatigue in women undergoing (neo)adjuvant chemotherapy for early‐stage breast cancer
title Objective physical and mental markers of self‐reported fatigue in women undergoing (neo)adjuvant chemotherapy for early‐stage breast cancer
title_full Objective physical and mental markers of self‐reported fatigue in women undergoing (neo)adjuvant chemotherapy for early‐stage breast cancer
title_fullStr Objective physical and mental markers of self‐reported fatigue in women undergoing (neo)adjuvant chemotherapy for early‐stage breast cancer
title_full_unstemmed Objective physical and mental markers of self‐reported fatigue in women undergoing (neo)adjuvant chemotherapy for early‐stage breast cancer
title_short Objective physical and mental markers of self‐reported fatigue in women undergoing (neo)adjuvant chemotherapy for early‐stage breast cancer
title_sort objective physical and mental markers of self‐reported fatigue in women undergoing (neo)adjuvant chemotherapy for early‐stage breast cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427709/
https://www.ncbi.nlm.nih.gov/pubmed/28061004
http://dx.doi.org/10.1002/cncr.30426
work_keys_str_mv AT mortimerjoannee objectivephysicalandmentalmarkersofselfreportedfatigueinwomenundergoingneoadjuvantchemotherapyforearlystagebreastcancer
AT walianysarah objectivephysicalandmentalmarkersofselfreportedfatigueinwomenundergoingneoadjuvantchemotherapyforearlystagebreastcancer
AT dieliconwrightchristinam objectivephysicalandmentalmarkersofselfreportedfatigueinwomenundergoingneoadjuvantchemotherapyforearlystagebreastcancer
AT patelsunitak objectivephysicalandmentalmarkersofselfreportedfatigueinwomenundergoingneoadjuvantchemotherapyforearlystagebreastcancer
AT hurriaarti objectivephysicalandmentalmarkersofselfreportedfatigueinwomenundergoingneoadjuvantchemotherapyforearlystagebreastcancer
AT chaojoseph objectivephysicalandmentalmarkersofselfreportedfatigueinwomenundergoingneoadjuvantchemotherapyforearlystagebreastcancer
AT tiepbrian objectivephysicalandmentalmarkersofselfreportedfatigueinwomenundergoingneoadjuvantchemotherapyforearlystagebreastcancer
AT behrendtcarolyne objectivephysicalandmentalmarkersofselfreportedfatigueinwomenundergoingneoadjuvantchemotherapyforearlystagebreastcancer